Enzychem Lifesciences Corporation (183490.KQ)
KRW 1329.0
(-2.71%)
KRW 1329.0
(-2.71%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -5.77 Billion KRW | 9.6% |
| 2022 | -13.15 Billion KRW | 33.41% |
| 2021 | -17.87 Billion KRW | -18.04% |
| 2020 | -15.71 Billion KRW | -9.25% |
| 2019 | -14.45 Billion KRW | -7.58% |
| 2018 | -12.63 Billion KRW | -251.99% |
| 2017 | -3.86 Billion KRW | 21.86% |
| 2016 | -4.78 Billion KRW | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -1.25 Billion KRW | 113.59% |
| 2024 Q2 | -2.75 Billion KRW | -1612.1% |
| 2023 Q4 | -2.78 Billion KRW | 16.45% |
| 2023 Q1 | -2.22 Billion KRW | 24.06% |
| 2023 Q2 | -2.87 Billion KRW | -28.92% |
| 2023 FY | - KRW | 9.6% |
| 2023 Q3 | -3.33 Billion KRW | -16.09% |
| 2022 Q2 | -3.02 Billion KRW | 25.1% |
| 2022 FY | - KRW | 33.41% |
| 2022 Q4 | -2.93 Billion KRW | -23.6% |
| 2022 Q3 | -2.37 Billion KRW | 21.39% |
| 2022 Q1 | -4.03 Billion KRW | 12.98% |
| 2021 Q1 | -5.06 Billion KRW | 17.34% |
| 2021 FY | - KRW | -18.04% |
| 2021 Q4 | -4.63 Billion KRW | -0.02% |
| 2021 Q3 | -4.63 Billion KRW | -7.17% |
| 2021 Q2 | -4.32 Billion KRW | 14.69% |
| 2020 Q4 | -6.13 Billion KRW | -27.57% |
| 2020 Q3 | -4.8 Billion KRW | -83.1% |
| 2020 Q1 | -3.51 Billion KRW | -23.44% |
| 2020 Q2 | -2.62 Billion KRW | 25.24% |
| 2020 FY | - KRW | -9.25% |
| 2019 Q3 | -4.72 Billion KRW | -19.27% |
| 2019 Q1 | -2.92 Billion KRW | -7.48% |
| 2019 FY | - KRW | -7.58% |
| 2019 Q4 | -2.84 Billion KRW | 39.77% |
| 2019 Q2 | -3.95 Billion KRW | -35.16% |
| 2018 FY | - KRW | -251.99% |
| 2018 Q2 | -2.12 Billion KRW | 64.52% |
| 2018 Q4 | -2.72 Billion KRW | -38.08% |
| 2018 Q3 | -1.97 Billion KRW | 6.91% |
| 2018 Q1 | -5.97 Billion KRW | -3072.94% |
| 2017 Q2 | -1.05 Billion KRW | 0.0% |
| 2017 FY | - KRW | 21.86% |
| 2017 Q3 | -1.16 Billion KRW | -10.54% |
| 2017 Q4 | -188.35 Million KRW | 83.83% |
| 2016 FY | - KRW | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| HLB Pharmaceutical Co., Ltd | 581.09 Million KRW | 1093.598% |
| CMG Pharmaceutical Co., Ltd. | 5.59 Billion KRW | 203.203% |
| Celltrion Pharm, Inc. | 54.22 Billion KRW | 110.648% |
| Huons Global Co., Ltd. | 151.92 Billion KRW | 103.8% |
| DongKook Pharmaceutical Co., Ltd. | 88.68 Billion KRW | 106.51% |
| Humedix Co., Ltd. | 54.87 Billion KRW | 110.522% |
| Boditech Med Inc. | 36.48 Billion KRW | 115.823% |
| EuBiologics Co., Ltd. | -4.39 Billion KRW | -31.465% |
| FutureChem Co.,Ltd | -591.25 Million KRW | -876.514% |
| Huons Co., Ltd. | 74.23 Billion KRW | 107.778% |
| BNC Korea Co., Ltd. | 14.17 Billion KRW | 140.742% |
| AptaBio Therapeutics Inc. | -13 Billion KRW | 55.603% |